Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China · Delayed Price · Currency is CNY 20.07
+0.79 (4.10%)
Sep 30, 2026, 3:00 PM CST
Aurisco Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8,096 | 10,175 | 8,579 | 10,488 | 10,029 | 8,830 | |
Market Cap Growth | -11.25% | 18.61% | -18.20% | 4.58% | 13.58% | 38.75% |
Enterprise Value | 8,345 | 10,126 | 8,317 | 10,056 | 9,726 | 8,296 |
Last Close Price | 20.07 | 24.63 | 20.47 | 24.79 | 23.56 | 20.89 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 22.02 | 22.65 | 24.18 | 36.24 | 47.54 | 52.34 |
Forward PE | - | 20.20 | 18.69 | 30.47 | 39.82 | 44.04 |
PS Ratio | 4.75 | 5.99 | 5.81 | 8.31 | 9.95 | 10.99 |
PB Ratio | 3.03 | 3.83 | 3.68 | 5.33 | 5.96 | 5.86 |
P/TBV Ratio | 3.22 | 4.08 | 3.95 | 5.68 | 6.46 | 6.02 |
P/FCF Ratio | 314.61 | 142.46 | - | 130.89 | - | - |
P/OCF Ratio | 19.56 | 24.14 | 25.81 | 27.20 | 60.27 | 43.81 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.90 | 5.97 | 5.64 | 7.97 | 9.65 | 10.33 |
EV/EBITDA Ratio | 12.91 | 15.53 | 17.73 | 28.49 | 35.61 | 35.42 |
EV/EBIT Ratio | 17.24 | 19.01 | 21.53 | 36.07 | 46.71 | 45.40 |
EV/FCF Ratio | 324.29 | 141.77 | - | 125.50 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.36 | 0.37 | 0.41 | 0.06 | 0.03 | 0.01 |
Debt / EBITDA Ratio | 1.50 | 1.48 | 2.00 | 0.33 | 0.19 | 0.08 |
Debt / FCF Ratio | 37.69 | 13.67 | - | 1.46 | - | - |
Net Debt / Equity Ratio | 0.09 | 0.01 | -0.05 | -0.22 | -0.20 | -0.28 |
Net Debt / EBITDA Ratio | 0.39 | 0.03 | -0.26 | -1.22 | -1.24 | -1.82 |
Net Debt / FCF Ratio | 9.68 | 0.31 | 0.58 | -5.35 | 6.81 | 8.70 |
Asset Turnover | 0.42 | 0.42 | 0.46 | 0.55 | 0.54 | 0.49 |
Inventory Turnover | 1.16 | 1.13 | 1.15 | 1.18 | 1.28 | 1.45 |
Quick Ratio | 2.59 | 2.67 | 2.68 | 1.69 | 1.92 | 3.06 |
Current Ratio | 4.16 | 3.95 | 3.85 | 2.73 | 3.38 | 4.87 |
Return on Equity (ROE) | 14.62% | 18.01% | 16.50% | 15.83% | 13.05% | 11.63% |
Return on Assets (ROA) | 7.49% | 8.22% | 7.49% | 7.56% | 6.93% | 7.02% |
Return on Invested Capital (ROIC) | 14.56% | 18.88% | 17.95% | 16.99% | 14.85% | 16.84% |
Return on Capital Employed (ROCE) | 13.00% | 14.40% | 11.60% | 13.40% | 12.20% | 12.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.61% | 4.42% | 4.14% | 2.76% | 2.10% | 1.91% |
FCF Yield | 0.32% | 0.70% | -2.42% | 0.76% | -0.50% | -0.56% |
Dividend Yield | 1.69% | 1.38% | 1.42% | 0.89% | 0.68% | 0.62% |
Payout Ratio | 38.65% | 27.63% | 26.72% | 23.15% | 24.81% | 28.52% |
Buyback Yield / Dilution | -3.34% | -2.44% | 2.21% | -0.48% | -1.00% | -7.31% |
Total Shareholder Return | -1.65% | -1.06% | 3.62% | 0.41% | -0.32% | -6.68% |